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Most polyene macrolide antibiotics are glycosylated
with mycosamine (3,6-dideoxy-3-aminomannose). In
theamphotericinBproducer,Streptomycesnodosus,
mycosamine biosynthesis begins with AmphDIII-
catalyzed conversion of GDP-mannose to GDP-4-
keto-6-deoxymannose. This is converted to GDP-
3-keto-6-deoxymannose, which is transaminated
to GDP-mycosamine by the AmphDII protein. The
glycosyltransferase AmphDI transfers mycosamine
to amphotericin aglycones (amphoteronolides). The
aromatic heptaene perimycin is unusual among poly-
enes in that the sugar is perosamine (4,6-dideoxy-4-
aminomannose),which is synthesizedbydirect trans-
amination of GDP-4-keto-6-deoxymannose. Here,
we use the Streptomyces aminophilus perDII peros-
amine synthase and perDI perosaminyltransferase
genes to engineer biosynthesis of perosaminyl-
amphoteronolide B in S. nodosus. Efficient produc-
tion required a hybrid glycosyltransferase containing
an N-terminal region of AmphDI and a C-terminal
region of PerDI. This work will assist efforts to
generate glycorandomized amphoteronolides for
drug discovery.INTRODUCTION
Many therapeutic agents are derived from polyketide and
peptide natural products that contain sugar residues (Wey-
mouth-Wilson, 1997). There is considerable interest in manipu-
lating the sugar moieties of these compounds in order to identify
analogs with improved pharmacological properties. Genetic
studies on producer organisms have given insights into deoxy-
hexose biosynthesis and provided glycosyltransferase (GT)
catalysts for addition of alternative sugars to aglycones. This
work has led to production of new compounds by genetic engi-
neering of producer strains and by in vitro glycosylation tech-
niques (Blanchard and Thorson, 2006; Thibodeaux et al., 2007;
Mendez and Salas, 2007). These studies have now been
extended to polyene macrolides, antifungal agents that are174 Chemistry & Biology 17, 174–182, February 26, 2010 ª2010 Elsealso active against parasites, enveloped viruses, and prions
(Zhang et al., 2008).
Most polyene antibiotics are glycosylated with mycosamine
(3, 6-dideoxy-3-amino-D-mannose). The aromatic heptaene
perimycin (Figure 1, 1) is unusual in that it contains perosamine
(4, 6-dideoxy-4-amino-D-mannose) (Pawlak et al., 1995). Peros-
amine also appears in the lipopolysaccharides of several gram-
negative pathogens, and its biosynthesis has been reconstituted
using enzymes from such organisms (Alberman and Piepers-
berg, 2001; Zhao et al., 2007). The pathway entails conversion
of GDP-mannose to GDP-4-keto-6-deoxymannose followed by
transamination (Figure 2). Genes involved in mycosamine
biosynthesis have been identified in several polyene-producing
streptomycetes (Caffrey et al., 2008). We have focused on Strep-
tomyces nodosus, which produces the medically important am-
photericin B (Figure 3, 2) alongwith a cometabolite, amphotericin
A (3). The current view of the mycosamine pathway in this
organism is shown in Figure 2. The AmphDIII GDP-mannose de-
hydratase catalyzes formation of GDP-4-keto-6-deoxymannose
that is converted to GDP-3-keto-6-deoxymannose. A transami-
nation catalyzed by the AmphDII protein generates the final acti-
vated sugar, GDP-mycosamine. It is unclear how the 3-ketosu-
gar intermediate is formed. No enzyme has yet been identified
that might catalyze 3, 4-ketoisomerisation of GDP-4-keto-6-
deoxymannose. In the course of biochemical studies on GDP-
fucose biosynthesis, Sullivan and co-workers (1998) used
Escherichia coli and human GDP-mannose 4, 6 dehydratases
to generate GDP-4-keto-6-deoxymannose in vitro. They ob-
tained NMR evidence for spontaneous conversion of this inter-
mediate to GDP-3-keto-6-deoxymannose. Thus, it is possible
that this step in mycosamine biosynthesis is not enzyme-
catalyzed in vivo. Spontaneous 3, 4 ketoisomerisation has also
been observed with dTDP-4-keto-6-deoxyglucose, a key inter-
mediate in the biosynthesis of many deoxyhexoses (Naundorf
and Klaffke, 1996). However, enzymes that catalyze this reaction
have been discoveredmore recently (Pfoestl et al., 2003). A well-
studied example is Tyl1a that operates in the mycaminose
biosynthetic pathway in Streptomyces fradiae, the tylosin
producer (Melanc¸on et al., 2007). This catalyzes interconversion
of the 4- and 3-ketosugars via an enediol intermediate (Tello
et al., 2008). Although Tyl1a has been extensively characterized,
the effects of disruption of the tyl1a gene on tylosin glycosylation
have not yet been investigated. Indeed, Schell and co-workers
have demonstrated biosynthesis of mycaminose in anvier Ltd All rights reserved
Figure 1. Structure of Perimycin
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4 ketoisomerase (Schell et al., 2008). These considerations
suggest that 3, 4 ketoisomerases may be important when it is
necessary to divert an NDP-4-keto-6-deoxyhexose away from
competing pathways, or when isomerization is accompanied
by a switch in alcohol stereochemistry at C-4. Neither of these
conditions applies in mycosamine biosynthesis.
The amphotericin aglycones are synthesized by a large
modular polyketide synthase (PKS) (Caffrey et al., 2001). The
initial products are 8-deoxy-16-descarboxyl-16-methyl-ampho-
teronolides A and B (4 and 5, Figure 3). The AmphN cytochrome
P450 oxidises the C-16 methyl group to a carboxyl group to form
8-deoxyamphoteronolides A and B (6 and 7). These are mycosa-
minylated by AmphDI and C-8 hydroxylated by AmphL to give
amphotericins A and B (2 and 3). Targeted inactivation of amphN
gives glycosylated amphotericin analogs, in which methyl
groups replace the exocyclic carboxyl groups (Carmody et al.,
2005). Deletion of both amphDII and amphN gave analogs 8
and 9 that lack exocyclic carboxyl groups and are glycosylated
with a 6-deoxyhexose, presumably a shunt product that results
from reduction of the 4-keto or the 3-ketosugar intermediate
by an unknown enzyme. The stereochemistry has not yet been
determined for C-3 and C-4 of the reduced sugar. These results
indicated that AmphDI might have some tolerance toward sugar
and aglycone substrates. However, Zhang and co-workers
(2008) performed in vitro studies with hexahistidine-tagged
forms of AmphDI and NysDI, the mycosaminyl transferase from
the nystatin producer Streptomyces noursei (Nedal et al.,
2007). Both enzymes were found to have narrow sugar substrate
specificity, recognizing only GDP-D-mannose and GDP-L-
gulose out of a panel of 21 synthetic GDP-sugars (Zhang et al.,
2008). GDP-perosamine was not investigated in this study.Figure
amine
and S.
Chemistry & Biology 17, 174–182, February 26, 2010Crystal structures have been deter-
mined for several plant and bacterial
GTs that act on bioactive natural prod-
ucts (Truman et al., 2009). Despite this
progress, only a few of these enzymes
have been successfully redesigned.
Sugar and aglycone substrate specific-ities have been altered by mutagenesis or by construction of
hybrid enzymes. In an early landmark study, Hoffmeister and
co-workers (2002) investigated extending glycosyltransferases
UrdGT1c and UrdGT1b that incorporate rhodinose and olivose,
respectively, as the second and third sugars in the linear trisac-
charide chain of urdamycins. Ten amino acids were shown to
determine donor and acceptor specificity. Mutagenesis of these
residues gave a GT that formed urdamycin P, which has
a branched trisaccharide chain. Another important example of
a redesigned GT is OleD, which normally catalyzes addition of
a glucosyl residue to C200 of the desosamine sugar of oleando-
mycin. Williams et al. (2007) performed high-throughput
screening to identify four key mutations that increase a weak
activity toward small aromatic acceptors. Saturation mutagen-
esis at three of these positions increased tolerance toward
NDP-sugar donors as well as acceptors (Williams et al., 2008a;
Williams et al., 2008b). Domain swapping can give a predictable
switch in GT substrate specificity. Thismethod has recently been
used to construct hybrid GTs that transfer alternative sugars
onto deoxystreptamine (Park et al., 2009) and glycopeptide
acceptors (Truman et al., 2009). The approach has also
expanded the range of flavonoid acceptors used by plant
UDP-glucosyltransferases (Hansen et al., 2009). However,
many hybrids are nonfunctional, possibly because artificially
fused NDP-sugar- and acceptor-binding domains may fail to
engage in interactions that are necessary for overall activity.
All of the GT engineering that has been performed so far has
been done with enzymes that use dTDP- or UDP-linked sugars.
PerDI and AmphDI use GDP-perosamine and GDP-mycos-
amine, respectively, and are not closely related to any natural
product GTs that have been redesigned or structurally charac-
terized. Here, we undertake the first, to our knowledge, in vivo2. Biosynthetic Pathways to GDP-Peros-
and GDP-Mycosamine in S. aminophilus
nodosus
ª2010 Elsevier Ltd All rights reserved 175
Figure 3. Amphotericins Discussed in This Work
2, amphotericin B; 3, amphotericin A; 4, 8-deoxy-16-descarboxyl-16-methyl-
amphoteronolide B; 5, 8-deoxy-16-descarboxyl-16-methyl-amphoteronolide
A; 6, 8-deoxyamphoteronolide B; 7, 8-deoxyamphoteronolide A; 8, 16-des-
carboxyl-16-methyl-19-O-deoxyhexosyl-amphoteronolide B; 9, 8-deoxy-16-
descarboxyl-16-methyl-19-O-deoxyhexosyl-amphoteronolide A; 10, 19-O-
deoxyhexosyl-amphoteronolide B; 11, 19-O-perosaminyl-amphoteronolide
B; 12, 16-descarboxyl-16-methyl-19-O-perosaminyl-amphoteronolide B.
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osamine biosynthesis and attachment were cloned from the
perimycin producer Streptomyces aminophilus. The PerDI
perosaminyl transferase is of interest because it transfers a sugar
other than mycosamine to a polyene macrolactone. In principle,
introduction of the perDII perosamine synthase gene into
S. nodosus should result in biosynthesis of GDP-perosamine.
We aimed to investigate whether AmphDI, PerDI, or engineered
GTs could synthesize perosaminyl-amphoteronolides. These
studies should assist further attempts to engineer the biosyn-
thesis of amphotericin analogs with altered sugar residues.RESULTS
Cloning of Perimycin Biosynthetic Genes
A cosmid library was constructed from genomic DNA of
S. aminophilus. The library was screened with DNA probes176 Chemistry & Biology 17, 174–182, February 26, 2010 ª2010 Elsederived from amphotericin PKS genes. Hybridizing cosmids
were isolated, and restriction fragments were subcloned into
pUC118 for limited sequencing. Sequences from the ends of
cosmid inserts were used to design oligonucleotide primers so
that overlapping clones could be identified by PCR. This
approach was used to assemble a set of cosmids representing
the entire cluster. The partial sequencing indicated that the orga-
nization of genes is similar to that in the candicidin/FR008 cluster
(Chen et al., 2003). Homologs of polyene glycosyltransferase
and sugar aminotransferase genes were found at one end of
the cluster. Complete sequencing of a 4919 bp region (GenBank
accession number, GQ380697) revealed perDI and perDII genes
for perosaminyltransferase and perosamine synthase. In the
sequenced region, the perDI gene was preceded by part of an
N-methylase gene, whereas perDII was followed by a discrete
thioesterase (TE) gene and the 50 end of a p-aminobenzoic
acid synthase (PABA) gene. N-Methylase and PABA synthase
enzymes are required for synthesis of the starter unit of the peri-
mycin polyketide. In Streptomyces species FR008, the region
immediately downstream from the fscMIImycosamine synthase
gene contains genes for a cytochrome P450 and ferredoxin that
catalyze formation of the exocyclic carboxyl group in FR008/
candicidin. This late modification does not occur in perimycin
biosynthesis, and the region between perDII and the discrete
TE gene consists of 76 bp of noncoding DNA.
PerDI shows 63–72% sequence identity with mycosaminyl
transferases, whereas PerDII shows 73–77% sequence identity
with mycosamine synthases (see Figure S1 available online).
Some of the differences between PerDII and mycosamine syn-
thases correspond to positions that have been identified as
active site residues in perosamine synthases from other bacteria
(Cook et al., 2008).
The perDIII gene for GDP-mannose 4, 6 dehydratase was
found at the opposite end of the cluster. Sequencing of a 3627
bp region (accession number, GQ380698) revealed that PerDIII
shows 76–81% sequence identity with GDP-mannose dehydra-
tases that function inGDP-mycosamine biosynthesis (Figure S1).
The upstream region contained a gene for a b-glucosidase
with strong homology to cellobiose hydrolases. This gene prob-
ably marks the end of the cluster because it has no obvious role
in perimycin biosynthesis. The downstream DNA contained
a 553 bp stretch homologous to the 50 end of fscD, which
encodes modules 11 to 16 of the FR008/candicidin PKS. Since
our main interest was in perosamine synthesis and attachment,
the remainder of the perimycin cluster was not sequenced at
this stage.
Inactivation of amphDII
Previous work had generated a DamphDII-NM mutant that
produced 16-descarboxyl-16-methyl-19-O-deoxyhexosyl am-
photeronolide B (8) and a tetraene analog (9) that is not C-8
hydroxylated (Carmody et al., 2005). This mutant retained a thio-
strepton resistance (tsr) gene embedded in the chromosome. In
this study, it was necessary to generate thiostrepton-sensitive
DamphDII mutants that could be transformed with plasmid
constructs that have tsr as a selectable marker. A frameshift
mutation was introduced into a cloned copy of the amphDII
gene by end-filling an internal NcoI site (nucleotides 63699–
63704; accession number AF357202). A StuI-PstI fragmentvier Ltd All rights reserved
Figure 4. Inactivation of amphDII
(A) Replacement of amphDIIwith amutant version results in loss of a chromosomal NcoI site (N). An adjacent BclI site (B) is unaffected. The small arrows represent
the BM1 and BM2 primers used to amplify the amphDII region from chromosomal DNA.
(B) Analysis of amphDII region in various strains. The amphDII region was amplified by PCR and treated with restriction enzymes. The wild-type amphDII region
contained the expected NcoI site (lane 1) whereas the corresponding sequences from the amphDII (lane 2) and amphDII-NM (lane 3) mutants did not. All three
PCR products were digested by BclI in control digests (lanes 4 to 6).
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sequence was cloned into KC-UCD1 (Carmody et al., 2004).
The resulting phage was used to replace the amphDII gene in
wild-type S. nodosus and in the DamphNM mutant. The geno-
types of the resulting DamphDII and DamphDII-NM mutants
were verified by PCR (Figure 4).
S. nodosus DamphDII produced polyenes with masses
consistent with 6-deoxyhexosyl-amphoteronolide B (10), agly-
cones 8-deoxyamphoteronolides A (5) and B (6), and amphoter-
onolide B (Figure S2). The mixture had no detectable antifungal
activity at total polyene concentrations as high as 50 mg/ml.
This was consistent with absence of the amino sugar. The fact
that all polyenes produced by this strain had exocyclic carboxyl
groups indicates that the frameshift mutation in amphDII does
not affect expression of the downstream amphN cytochrome
P450 gene. S. nodosus DamphDII-NM produced 6-deoxyhexo-
sylated polyenes lacking exocyclic carboxyl groups (8 and 9) de-
tected previously by Carmody et al., (2005) as well as aglycones
8-deoxy-16-descarboxyl-16-methyl-amphoteronolides A and B
(4 and 5).
The amphDII gene was amplified and cloned into the expres-
sion vector pIAGO (Aguirrezabalaga et al., 2000) under the
control of the ermE promoter. The resulting pIAGO-amphDII
construct was transformed into S. nodosus DamphDII and
S. nodosus DamphDII-NM. The plasmid-borne amphDII gene
restored efficient production of active mycosaminylated ampho-
tericins in both strains (data not shown).
Attempts to Engineer the Biosynthesis
of Perosaminyl-Amphoteronolides
Previous inactivation of the amphDIII gene gave a mutant that
synthesized 8-deoxyamphoteronolide A (7) as a major productChemistry & Biology 17, 174(Byrne et al., 2003). The perDIII gene was cloned into pIAGO
and transformed into S. nodosus DamphDIII. Analysis of polyene
extracts revealed that the resulting transformant produced
a mixture of aglycone 7 and glycosylated amphotericins 2 and
3 in approximately equal amounts (data not shown), whereas
the host containing the empty vector synthesized aglycone 7
only. The fact that PerDIII can substitute for AmphDIII is consis-
tent with the proposed mycosamine biosynthetic pathway
shown in Figure 2. In S. nodosus, the PerDII protein should be
able to intercept GDP-4-keto-4, 6-dideoxymannose, produced
by AmphDIII, and catalyze formation of GDP-perosamine.
We first attempted to replace the S. nodosus chromosomal
amphDI-DII genes with perDI-DII genes. This was expected to
reveal whether PerDI could transfer perosamine onto amphoter-
icin aglycones. A recombinant phagewas constructed to contain
the perDI-DII genes flanked by sequences upstream and down-
stream of the amphDI-DII-NM region. The perDI start codon was
precisely located downstream from the amphDI promoter and
ribosome-binding site. Attempts to perform the gene replace-
ment in S. nodosus DNM yielded a deletion mutant lacking
amphDI-DII-NM and containing perDI-DII (Figure S3), which
had the required genotype. This strain produced low levels of
aglycones 4 and 5 but no glycosylated forms (Figure S4). This
finding provided evidence that PerDI does not recognize ampho-
teronolides lacking exocyclic carboxyl groups, even though
these aglycones resemble its natural substrate around the glyco-
sylation site. Attempts to obtain a perfect replacement of
amphDI-DII by perDI-DII were therefore discontinued.
The 8-deoxy-16-descarboxyl-16-methyl amphoteronolide B
product (4) had a lower methanol-solubility than other amphoter-
onolides and precipitated selectively on partial concentration of
crudemethanol extracts. It could be purified in 100mg quantities–182, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 177
Figure 5. Detection of Perosaminylated Polyene by HPLC
(A) HPLC analysis of polyenes produced byS. nodosusDamphDII transformed
with pIAGO.
(B) Polyenes extracted from the same host carrying pIAGO-perDII.
(C) Polyenes from the strain carrying pIAGO-hap2 encoding the Hap2 hybrid
GT and PerDII.
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genes. Structural analysis of this material by NMR will be
described elsewhere. This aglycone may be useful for in vitro
studies on polyene glycosylation and exocyclic carboxyl group
formation.
The pIAGO-perDII plasmid was introduced into S. nodosus
DamphDII. Crude polyenes extracted from this transformant
showed some antifungal activity. Analysis of the extract by
HPLC revealed a low level of a new polyene, in addition to those
produced by the host strain containing the empty vector, 8-de-
oxyamphoteronolide B (6) and 6-deoxyhexosyl-amphoterono-
lide B (10) (Figures 5A and 5B). The new compound was a minor
component and made up 2% of the total polyene. Further anal-
ysis revealed that this compound had a mass appropriate for 11.
The yield of this product was too low to allow further purification
and analysis. This result suggested that AmphDI can perosami-
nylate amphoteronolides, but very inefficiently. The fact that the
deoxyhexosylated analog 10 remained as the major product
suggests that AmphDI has a preference for GDP-deoxyhexose
over GDP-perosamine. Overproduction of AmphDI was not
expected to change the proportions of polyene products or to
increase the yield of 11. Attempts were therefore made to
construct a hybrid GT.Assessment of AmphDI-PerDI Hybrid GTs
The GTs involved in natural product glycosylation belong to the
GT-B superfamily and have N-terminal and C-terminal domains
that function in recognition of acceptor and NDP-sugar donor
substrates, respectively. In an effort to increase the yield of the
putative perosaminylated analog, hybrid GTs were constructed
in which the putative 8-deoxyamphoteronolide-binding N-ter-
minal domain of AmphDI was fused to the putative GDP-178 Chemistry & Biology 17, 174–182, February 26, 2010 ª2010 Elseperosamine-binding C-terminal domain of PerDI. The internal
boundaries of these substrate-binding domains were uncertain,
because PerDI and themycosaminyl transferases are not closely
related to natural product GTs that have been characterized
more extensively (Liang and Qiao, 2007). It was therefore neces-
sary to identify a functional cross-over point by trial and error.
Two hybrid genes were made in initial attempts to design a GT
that could efficiently modify the amphotericin aglycone with
perosamine. To construct the first of these, the OGTF and
GTR1 primers were used to amplify the 50 region of the amphDI
gene from the ribosome-binding site to the codons for E191-
L192. The GTF1 and OGTR primers were used to amplify the
S. aminophilus DNA region from the corresponding perDI
codons for E191-L192 to the end of perDII. In both AmphDI
and PerDI, E191-L192 are encoded by GAG-CTG codons. In
each case, the second codon was altered so as to create a
SacI site (GAGCTC). The two products were ligated through their
SacI sites to create a hybrid amphDI-perDI gene (hap1) linked to
a perDII gene. This DNA was cloned between the BamHI and
HindIII sites of pIAGO to form pIAGO-hap1.
The second hybrid GT gene (hap2) was constructed using
primer pairs OGTF plus GTR3 and GTF3 plus OGTR. In this
case, the two products were joined through a SacI site intro-
duced to represent GAG-CTC codons for E246-L247 of AmphDI
and E244-L245 of PerDI. The second construct was named
pIAGO-hap2. The cross-over points in Hap1 and Hap2 are high-
lighted in Figure S1A.
The pIAGO-hap1 and pIAGO-hap2 plasmids were introduced
into the DamphDII and DamphDII-NM mutants. The two
constructs differ at only 59 nucleotide positions in a central
165 bp stretch within the GT gene. Thus, the expression levels
of the two hybrid genes are expected to be similar. In the Damp-
hDII strain, pIAGO-hap1 had the same effect as pIAGO-perDII
but pIAGO-hap2 increased the yield of the new analog (11) to
approximately 25%of the total polyene, andbrought about a cor-
responding decrease in the amount of the aglycone 6 (Fig-
ure 5C). This change was caused by the hap2 gene because
the strains are otherwise isogenic. In an additional control exper-
iment, a pIAGO-perDI-perDII construct did not elevate produc-
tion of the new polyene, confirming that PerDI does not recog-
nize amphoteronolides even when expressed from the ermE
promoter. These results show that Hap2 is a functional hybrid
GT in which the amphoteronolide-binding domain of AmphDI
has been grafted onto the GDP-perosamine-binding domain of
PerDI. Although the two hybrid proteins differ by only 24 amino
acids out of 460, Hap2 boosted production of 11, whereas
Hap1 did not. This shows that the choice of cross-over point is
critical. It should be noted that the pIAGO vector does not give
particularly high expression of cloned genes in S. nodosus.
None of the GTs (AmphDI, PerDI, Hap1, or Hap2) could be
detected as a prominent band when cell lysates of the various
transformants were analyzed by SDS-polyacrylamide gel
electrophoresis.
The new compound had a retention time different to that of
amphotericin B (Figure S5). The mass was that expected for per-
osaminyl-amphoteronolide B (11) ([MH ] = 922.5; [M + Na]+ =
946.5) (Figure S6). The yields of the new polyene fromS. nodosus
DamphDII pIAGO-hap2were typically around 40 mg/L. No pero-
saminylated tetraenes were observed.vier Ltd All rights reserved
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The analog was purified and examined by proton and COSY
NMR. Most resonances are similar to those found in amphoter-
icin B (Figures S7 and S8). The four methyl groups in amphoter-
icin B show NMR resonances in d6-DMSO as doublets at 0.91,
1.04, 1.11, and 1.13 ppm (McNamara et al., 1998), the last as-
signed to the mycosaminyl methyl group. NMR analysis of
HPLC-purified 11 (2 mg) in DMSO at 40C showed four methyl
doublets at 0.93, 1.05, 1.13, and 1.17 ppm; this last value has
moved downfield, and the resonance was considerably broad-
ened. Addition of an equivalent of methanoic acid to the NMR
sample sharpened this doublet, and moved it further downfield
to 1.24 ppm, presumably because of the close proximity in
space of the perosaminyl’s equatorial protonated 4-amino
group. The resonance at 2.81 ppm, assigned to the 40-CH(NH2)
proton, shows two large transdiaxial coupling constants of
9.5 Hz to 3.37 ppm (50) and 3.44 (30). The 20-proton at 3.70
ppm has a small axial/equatorial coupling constant of 2.7 Hz to
the 30-proton. The 10-proton has moved from 4.61 in amphoter-
icin B upfield to 4.35 ppm in the perosaminyl analog. Reported
NMR analysis of N-acetyl perimycin in deuterated pyridine/
methanol has coupling constants for 20 of 0.0 and 3.0 Hz; those
for 30 are 3.0 and 10.0, and those for 40 are 10.0 and 10.0 (Pawlak
et al., 1995).
Perosaminylation of Amphoteronolides Lacking
Exocyclic Carboxyl Groups
The pIAGO-hap2 plasmid was also introduced into the S. nodo-
susDamphDII-NM strain that produces aglycones lacking exocy-
clic carboxyl groups. This resulted in formation of a new minor
polyene product not produced by the parent strain. Analysis by
ESMS indicated that 16-descarboxyl-16-methyl-19-O-perosa-
minyl-amphoteronolide B (12) was produced ([M + H]+ = 894.5;
[M  H2O + H]+ = 876.5]; [M + Na]+ = 916.5; formic acid adducts
were detected in negative ion mode ([M + HCOOH] = 938.5). It
was not possible to purify this minor component in quantities
sufficient for further analysis. However, it can be concluded that
the Hap2 GT is capable of transferring perosaminyl residues to
amphoteronolides lacking exocyclic carboxyl groups.
Biological Activities of 19-O-Perosaminyl-
Amphoteronolide B
Bioassays against Saccharomyces cerevisiae indicated that per-
osaminyl-amphoteronolide B had a minimal inhibitory concen-
tration of 1.9 mg/ml. In parallel control assays, amphotericin B
had an MIC of 2.1 mg/ml. The two polyenes also had approxi-
mately the same hemolytic activity. The polyene concentrations
giving 50% hemolysis (MHC50 values) were 3.125 and 3.7 mg/ml
for perosaminyl-amphoteronolide B and amphotericin B, re-
spectively, indicating similar potential toxicity. Thus, replacing
mycosamine with perosamine may have only a small overall
positive effect on these biological activities. However, the chro-
matographic properties of 11 show that it is slightly more water
soluble than amphotericin B.
DISCUSSION
Enzymatic glycorandomization of polyene macrolides will
require libraries of NDP-sugar donors and sugar-flexible GTs.Chemistry & Biology 17, 174Chemical and enzymatic methods have been developed for
synthesis of NDP-sugars. These methods have already been
used to synthesize 18 different GDP-sugars in vitro. Mendez
and Salas, (2007) have assembled plasmid constructs that direct
intracellular synthesis of 12 different dTDP-deoxyhexoses.
A similar approach might be possible for in vivo generation of
up to nine naturally occurring GDP-sugars (D-rhamnose,
D-mannose, L-fucose, L-colitose, L-gulose, L-galactose, D-altrose,
6-deoxy-D-talose, and L-fucofuranose). Prospects for generating
unnatural NDP-sugars in vivo have also been discussed
(Hui et al., 2007; Nic Lochlainn andCaffrey, 2009). Although tech-
nologies for generating NDP-sugars are advanced, previous
studies indicated that polyeneGTsshow limited tolerance toward
these alternative substrates. To our knowledge, this work takes
the first step toward addressing this issue.
Here, our in vivo studies indicate that the PerDI perosaminyl
transferase does not act on amphotericin aglycones and that
the AmphDI mycosaminyl transferase inefficiently recognizes
GDP-perosamine. In the DamphDII strain containing pIAGO-
perDII, AmphDI generated small amounts of perosaminyl-am-
photeronolide B. This represents the first example of rational
engineering of polyene macrolide glycosylation. Introduction of
the Hap2 hybrid GT significantly increased the yield of perosa-
minyl-amphoteronolide B. This shows that the aglycone-speci-
ficity of PerDI has been modified. To date, only a few natural
product GTs have been redesigned successfully. To our knowl-
edge, this is the first example involving a GT that acts directly on
a complex polyketide macrolactone.
The activity of Hap2 indicates that the AmphDI region from
residues 1 to 247 functions in aglycone recognition, whereas
the PerDI region from residues 248 to 458 is capable of binding
GDP-perosamine. This finding is important because it should
guide efforts to graft the amphoteronolide-binding domain onto
C-terminal domains that recognize dTDP-glucose-derived deox-
yhexoses. A greater array of these sugars is available. In addi-
tion, GDP-perosamine and GDP-mycosamine binding domains
can be fused to N-terminal domains of GTs that recognize other
natural product aglycones.
The S. nodosus DamphDII pIAGO-hap2 transformant retains
a functional amphDI gene and produces 6-deoxyhexosyl-am-
photeronolide B as well as 19-O-perosaminyl-amphoteronolide
B. Formation of the GDP-deoxyhexose apparently competes
with GDP-perosamine biosynthesis in this strain. It is possible
that GDP-4-keto-6-deoxymannose undergoes rapid 3, 4-ketoi-
somerisation and/or reduction. Sequence analysis of the
S. nodosus genome may help to identify candidate genes for
the 3,4 ketoisomerase, if it exists, and the reductase. This will
allow deletion of pathways that divert GDP-4-keto-6-deoxyman-
nose away from biosynthesis of alternative GDP-sugars.
Replacing the mycosamine of amphotericin B with peros-
amine made little difference to antifungal or hemolytic activity.
This was not surprising, because previous chemical modification
studies have shown that, although a positive charge on the sugar
residue is essential for antifungal activity of amphotericin B, its
exact location is not critical (Cheron et al., 1988). Recently,
a Streptomyces species was identified that naturally produces
an analog of pimaricin in which mycosamine is replaced by per-
osamine (Komaki et al., 2009). The perosaminylated analog had
a 4-fold decrease in antifungal activity relative to pimaricin. The–182, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 179
Table 1. Oligonucleotides Used in This Study
















Redesign of Amphotericin Glycosylationmode of action of pimaricin is different from that of other poly-
enes (te Welscher et al., 2008). This may explain why moving
the sugar amino group has a greater impact on activity in the
case of pimaricin. At neutral pH, amphotericin B exists as a zwit-
terion in which the positive charge on the amino sugar neutral-
izes the negative charge on the exocyclic carboxyl group. With
perosaminyl-amphoteronolide B, increased separation of these
charges appears to improve water-solubility slightly.
Although the aminosugar of amphotericin B is important for
antifungal activity, preliminary evidence suggests that it may
not be essential for other biological effects, such as antiprion
activity (Soler et al., 2008). Some of these additional activities
might be enhanced by glycosylation engineering. The work re-
ported here will enable the potential of polyene macrolides to
be explored more fully.
SIGNIFICANCE
The biosynthesis of 19-O-perosaminyl-amphoteronolide B is
the first rational redesign of polyene glycosylation bygenetic
engineering of a producermicroorganism. Production of this
compound ingoodyield suggests that sustainable fermenta-
tionmethodswill be able todeliver valuable glycoengineered
analogs in quantities sufficient for clinical development.
Polyene macrolide GTs and are not closely related to previ-
ously characterized GTs and use GDP-sugar donors
rather than dTDP- or UDP-linked sugars. The construction
of an active AmphDI-PerDI hybrid shows that aglycone-
and NDP-sugar-binding domains can be also exchanged
between these polyeneGTs. The C-terminal regions of these
enzymes can now be targeted in attempts to increase sugar
flexibility. This workwill assist future attempts at glycodiver-
sification of polyene macrolides and other natural products.
EXPERIMENTAL PROCEDURES
DNA Methods
S. aminophilus DSM 40057 was obtained from DSMZ. Total cellular DNA was
isolated as described by Hopwood et al. (1985). Chromosomal DNA was
partially digested with Sau3A1 and fragments in the size range 30 to 40 kb180 Chemistry & Biology 17, 174–182, February 26, 2010 ª2010 Elsewere purified by sucrose density gradient centrifugation. These fragments
were ligated to BamHI-cut pWE15 cosmid vector DNA and packaged into
lambda phage particles using a Promega Packagene kit. The library was prop-
agated on E. coli XL-Blue MR.
DNA probes were prepared from the amphotericin cluster. The insert from
cosmid 4 containing the amphC sequence and the insert from cosmid 16 con-
taining the amphI sequence were used as PKS probes. Fragments were puri-
fied by preparative agarose gel electrophoresis and labeled with digoxygenin-
linked dUTP using a Boehringer Mannheim nonradioactive labeling kit. DNA
labeling, colony hybridization, and Southern hybridization were performed
according to the manufacturer’s instructions. Deep Vent DNA polymerase
was used in PCRs. DNA sequencing and resequencing was performed by
MWG Biotech.
To construct pIAGO-perDIII, pIAGO-perDII, and pIAGO-amphDII, the indi-
vidual genes were amplified with the forward and reverse primers listed in
Table 1 The PCR products were digested with BamHI-HindIII or BglII-HindIII
and cloned between the BamHI and HindIII sites of the pIAGO expression
plasmid. The pIAGO-hap1 and pIAGO-hap2 plasmids were constructed as
described in the Results section.
The pIAGO-perDI-DII construct was assembled as follows. A plasmid sub-
clone CBY was digested at an EcoRI site just upstream from the perDI start
codon and ribosome-binding site. The cohesive end was repaired with T4
DNA polymerase. Digestion with HindIII excised a fragment corresponding to
nucleotides 484–4919 of the sequenced region (GenBank accession number
GQ380697). Ligation between the HindIII and end-repaired BamHI sites of
pIAGO positioned the perDI-DII region downstream from the ermE promoter.
Protoplast transformations and gene replacements were performed as
described elsewhere (Carmody et al., 2004; Power et al., 2008).
General Polyene Purification
Polyenes were purified and characterized as described elsewhere (Power
et al., 2008). Production cultures were grown in 2-l flasks containing 5 g fruc-
tose, 15 g dextrin (Corn, Type II, 15% soluble), 7.5 g soybean flour (Type I), 2.5g
CaCO3, 12.5 g Amberlite XAD16 resin, and 250 ml deionized water. Flasks
were shaken at 120 rpm (32 mm gyrotary) at 28C for 3 days. Polyenes were
extracted from sedimented mycelia and resin into methanol. Rotary evapora-
tion was used to concentrate the methanol extract to an aqueous residue from
which the polyenes precipitated. The precipitate was washed first with water
and then with chloroform. Drying gave a yellow powder containing partially
purified mixed polyenes.
Large-Scale Purification of 19-O-Perosaminyl-Amphoteronolide
B (11)
The mycelia and beads from a 7 L culture (28 flasks) were harvested by centri-
fugation (Sorvall GSA, 10,000 rpm 10 min, 4C). The combined pellets werevier Ltd All rights reserved
Chemistry & Biology
Redesign of Amphotericin Glycosylationfinely dispersed in 7 L methanol and left to soak for 18 hr. The suspension was
centrifuged and the supernatant extract was retained. The resulting pellet was
re-extracted with a further 7 L methanol. Assay of the combined methanol
extracts by UV spectrophotometry (Shimadzu 2401 PC) gave 880 mg
heptaenes and 950 mg tetraenes (i.e., 125 mg/L heptaenes and 135 mg/L
tetraenes). The extinction coefficient (3) for monomeric amphotericin B at
405 nm is 1.7 3 105 M1cm1. For amphotericin A, 3 is 0.78 3 105 M1cm1
at 318 nm.
The total methanolic extract was concentrated in vacuo (below 40C) until
a yellow precipitate formed. This was harvested by centrifugation. The initial
precipitate contained 750 mg heptaenes and 400 mg tetraenes. Washing
with deionizedwater (23 50ml) gave 700mg heptaenes and 100mg tetraenes.
After freeze drying, the total dry weight of yellow powder was 1.2 g.
Further purification was performed on a Varian Prostar 210 diode array
HPLC with Galaxieworkstation software and UV Diode array detector. The
columns (Supelco Ascentis) were C8 reverse phase silica, 5 mm particle size,
and 25 cm length. The 4.6 mm diameter analytical column was run at a flow
rate of 1mL/min with sample volumes of 0.02ml in methanol. A 21.2 mmdiam-
eter preparative column was run at a flow rate of 14.8 mL/min with a typical
injection volume of 1.0 ml in DMSO. The solvent system was water (A) and
methanol containing 0.1% v/v formic acid (B). The gradients were typically
50–90% B over 28 min.
Polyene Analysis
Low-resolution electrospray mass spectrometry was performed on a triple
Quadropole Micromass Quattro LC instrument. High-resolution mass spec-
trometry was performed using a Kratos Concept 1H double-focusing high-
resolution sector instrument. FAB (Fast atom bombardment) spectroscopy
was performed using 3-nitrobenyl alcohol matrix with HRMS peak matching
referenced to stable reference peaks.
NMR spectra were obtained using a Bruker AV500 MHz instrument. A
sample of perosaminyl-amphoteronolide B (11) was purified twice by HPLC
to obtain 2 mg. This was dissolved in d6-DMSO and analyzed at room temper-
ature (298 K) with the water peak suppressed.
Antifungal and haemolytic activities were assayed as described elsewhere
(Carmody et al., 2005).
ACCESSION NUMBERS
The sequences of the perDI-DII region and the perDIII region have been depos-
ited in the GenBank database with accession numbers GQ380697 and
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